Travel vaccines: the whole arc, one analysis.
The existing-vaccine module is complete - travel-attributed sales isolated from endemic and routine use, and split to country level across 13 vaccines and 13 markets. The forecast to 2040 is in preparation, framed in three scenarios anchored to IATA long-term air passenger demand, and scopes the emerging development pipeline.
Private preview for selected clients | figures reserved. From VacZine Analytics MarketVIEW: Travel Vaccines (VAMV090). Analysis current July 2026.
de-layered from franchises
US/Canada | EU5 | Nordics | JP/KR/AU
each anchored & weighted
three IATA-anchored scenarios
From pandemic collapse to recovery - and modelled to 2040
We track the traveller vaccine market across its full arc: the pandemic trough, the recovery powered by returning travel and new launches (chikungunya, dengue), and a forward view to 2040. Travel-attributed sales are separated cleanly from endemic and routine use - the traveller market on its own terms.
Country-specific - to the cell
Every one of the 13 vaccines is split across 13 markets: 169 country-level estimates, each anchored to disclosed company actuals where they exist, then apportioned by pathogen-specific outbound travel and graded by confidence. Not a top-down guess - a bottom-up build.
Demand modelled, not assumed
Each vaccine is weighted by destination-specific outbound travel - rabies-endemic regions, Japanese encephalitis in rural Asia, the meningitis belt plus Hajj and Umrah pilgrimage, yellow-fever entry mandates, the Aedes tropics for dengue and chikungunya, and TBE forest zones. Pathogen risk, entry mandates and pilgrimage, market by market.
Confidence, made explicit
Every figure is graded so its reliability is visible. The large majority of lines are anchored to disclosed company actuals or audited regional splits; only two are fully modelled and flagged as directional. You always know where the evidence is strongest.
Where each product can actually sell
Revenue is only allocated where a product is licensed. The traffic-light map captures traveller-market availability across the modelling countries - the newer franchises (chikungunya, dengue) carry the sharpest restrictions.
Request the country-level figures and 2040 scenarios
This preview shows the structure and depth of the analysis; the absolute values, full country splits and forecast scenarios are reserved for clients. Contact us for a private walkthrough or to license the report.
View the report page Request a briefing